Inhibiting IL-17A signaling in the horse will not be as simple as applying human therapies since the most successful psoriasis treatments use monoclonal antibodies to block IL-17A receptor activation [21]; these antibodies may not bind the equine IL-17A receptor, may be antigenic in equines, and are likely cost-prohibitive. Here, IL17RA is linked to psoriasis.